Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)
Close on Nov 13, 2026Market cap $7.92BP/E –Yield –
Rhythm Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Rhythm Pharmaceuticals's total debt was $106.10M at Jun 30, 2026. For fiscal 2025 it was $108.18M, down 1.5% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.18M | -1.5% |
| FY2024 | Dec 31, 2024 | $109.81M | +3.5% |
| FY2023 | Dec 31, 2023 | $106.14M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $106.10M | -3.4% |
| Q1 FY2026 | Mar 31, 2026 | $108.47M | -1.0% |
| Q4 FY2025 | Dec 31, 2025 | $108.18M | -1.5% |
| Q3 FY2025 | Sep 30, 2025 | $108.97M | +2.7% |
| Q2 FY2025 | Jun 30, 2025 | $109.79M | – |
| Q1 FY2025 | Mar 31, 2025 | $109.52M | – |
| Q4 FY2024 | Dec 31, 2024 | $109.81M | – |
| Q4 FY2023 | Dec 31, 2023 | $106.14M | – |
See a number that looks wrong?